Biotech Eyes Tax Revamp as Next Chance to Shake Its Recent Woes

(Bloomberg) -- Biotechnology investors who saw their portfolios stumble after a late-summer bull run may refocus on a key reason that the group took off: the U.S. tax overhaul and repatriation.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.